Profil de l'entreprise BIOALLIANCE Pharma SA
Presse économique
--(BUSINESS WIRE)--BioAlliance Pharma est une société biopharmaceutique à responsabilité limitée, spécialisée dans le développement et la commercialisation de thérapies novatrices et tests prédictifs visant à combattre la résistance aux médicaments qui apparaît lors d'un cancer ou de maladies infectieuses, y compris en cas de VIH.
(BW) Company Profile for BioAlliance Pharma
SA
Business Editors
--(BUSINESS WIRE)--BioAlliance Pharma is a privately held
biopharmaceutical company focused on the development and
commercialization of innovative therapeutics and predictive assays in
the field of drug resistance, targeting cancer and infectious
diseases, including in particular HIV. The Company has a balanced
portfolio of products and proprietary technologies in various stages
of development, from preclinical research to a product approved for
marketing. To supply this pipeline of products, BioAlliance maintains
a unique network of alliances with leading academic investigators from
French research institutions, including Le Centre National de la
Recherche Scientifique (CNRS), L'Institut National de la Sante et de
la Recherche Medicale (INSERM) and the Institut Pasteur, among others.
To exploit the opportunities represented by the BioAlliance
pipeline, the company emphasizes four areas of product development:
Predictive Assays, with a HIV drug resistance test,
Phenoscript(TM), currently marketed through distribution partnerships
in the US and Europe;
Adhesive Technology, with a lead product represented by
Miconazole-Lauriad(TM), a once-a-day buccal bio-adhesive tablet
developed to provide improved therapy for treatment of candidiasis in
cancer and HIV patients receiving chemotherapy or immuno-suppressive
drugs. Miconazole-Lauriad(TM) is currently in two Phase III clinical
trials in France in head and neck cancer patients following
radiotherapy and in HIV patients. The Company plans to file an IND for
clinical studies in the US, pending a corporate partnership;
Nanotechnology, focused on a portfolio of products including the
Transdrug(TM) program with an initial product, Doxorubicin-Transdrug,
in a Phase I/II trial being conducted at clinical sites in France for
treatment of hepatocellular carcinoma (HCC). Doxorubicin-Transdrug
consists of a proprietary polymer used to entrap doxorubicin
administered by the intra-arterial route to treat primary liver
cancer. HCC is a known resistant cancer without an approved therapy.
Additional studies using this delivery nanotechnology are planned for
treatment of liver metastasis and refractory solid tumors by the IV
route;
New Chemical Entities, focused on resistance issues in HIV and
cancer that could benefit from intra-cellular targeting, including an
anti-HIV integrase inhibitor and cancer drugs covered by 20 exclusive
patents and licenses.
For additional company background, please visit the BioAlliance
Pharma web sites at: www.BioAlliancepharma.com and
www.viralliance.com.
Company: BioAlliance Pharma SA
Headquarters Address:
59, boulevard du General Martial Valin
75015 Paris
France
Main Telephone: +33 (0) 1 45 58 76 00
Website:
www.bioalliancepharma.com
Type of Organization:
Private
Industry:
Health: Biotechnology
Key Executives:
CEO: Dominique Costantini
COO: Gilles Avenard
Vice President, Business Development:
Richard Keatinge
Public Relations
Contact: Richard Keatinge
Phone: +33 (0) 1 45 58 76 00
Email: richard.keatinge@bioalliancepharma.com
(C) CompanynewsGroup